News

Derivatives marketplace CME Group (NASDAQ:CME) was downgraded at UBS over a recent slowdown in activity after a strong ...
Fintel reports that on July 24, 2025, UBS downgraded their outlook for CME Group (NasdaqGS:CME) from Buy to Neutral. Analyst ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $296.57, ...
In recent trading, shares of CME Group Inc (Symbol: CME) have crossed above the average analyst 12-month target price of $270.39, changing hands for $272.36/share. When a stock reaches the target ...
In a report released today, Patrick O’Shaughnessy from Raymond James maintained a Buy rating on CME Group, with a price target of $309.00. The company’s shares opened today at $274.22. Take advantage ...
On June 4, Oppenheimer raised its price target on CME Group Inc. (NASDAQ:CME) to $300 from $282, maintaining an Outperform rating, as recent trading activity points to heightened market engagement ...
BofA raised the firm’s price target on CME Group (CME) to $219 from $200 and keeps an Underperform rating on the shares. The increasingly uncert ...
J.P. Morgan analyst Ken Worthington maintained a Sell rating on CME Group on July 21 and set a price target of $245.00. The company’s shares closed yesterday at $274.64. Take advantage of TipRanks ...
CME Group (NASDAQ:CME – Free Report) had its target price increased by Barclays from $263.00 to $279.00 in a research note published on Monday,Benzinga reports.
Barclays raised the firm’s price target on CME Group (CME) to $283 from $279 and keeps an Equal Weight rating on the shares following the Q1 report. The company saw record volumes across ...
Return on Equity (ROE): CME Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing ...